Attorney's Docket No.: 06275-518US1 / 101318-1P US

Applicant: Lilian Alcaraz et al. Serial No.: 10/587,633 Filed: July 28, 2006

Page : 2 of 8

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-14. (Cancelled)

15. (New) A compound of formula (I):

$$R^{1}$$
 \sim N \sim CH_{2} \sim N \sim CH_{2} \sim N \sim R^{3} \sim (1)

wherein:

 R^1 is phenyl optionally substituted by halogen, cyano, C_{1-4} alkyl or C_{1-4} haloalkyl; R^2 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl; and,

R³ is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0; or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

- 16. (New) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, or solvate thereof, or a solvate of a salt thereof, as claimed in claim 15, and a pharmaceutically acceptable adjuvant, diluent or carrier therefor.
- 17. (New) A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, as claimed in claim 15.

Applicant: Lilian Alcaraz et al. Attorney's Docket No.: 06275-518US1 / 101318-1P US

Serial No. : 10/587,633 Filed : July 28, 2006 Page : 3 of 8

18. (New) The compound of claim 15, wherein the acidic NH of R³ is part of a ring or part of a substituent on an aryl or heterocyclyl ring.

- 19. (New) The compound of claim 18, wherein the acidic NH of \mathbb{R}^3 is part of a pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl, triazolyl, pyridinyl or pyrimidinyl ring.
- 20. (New) The compound of claim 18, wherein the acidic NH of R³ is part of a substituent on a phenyl, naphthyl, furyl, thienyl, pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, pyridinyl or pyrimidinyl ring.
- 21. (New) The compound of claim 18, wherein the acidic NH of R³ is part of a 2-oxo-thiazol-5-yl, 2-oxo-oxazol-5-yl, 2-oxo-imidazol-5-yl, 1H-1,2,3-triazol-4-yl, 4-oxo-1H-1,4-dihydropyridin-3-yl, 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl, 6-oxo-1H-1,6-dihydropyridin-3-yl or 2H-tetrazol-5-yl ring.
- 22. (New) The compound of claim 18, wherein the acidic NH of \mathbb{R}^3 is part of a NHS(O)₂(C₁₋₄ alkyl) substituent.
- 23. (New) The compound of claim 15, wherein the acidic OH of R³ is a substituent or part of a substituent on an aryl or heterocyclyl ring.
- 24. (New) The compound of claim 23, wherein the acidic OH of R³ is in a carboxylic acid group.
- 25. (New) The compound of claim 23, wherein the acidic OH of R³ is part of an acidic phenol in a carboxylic acid or in a hydroxy aromatic heterocyclyl.

Applicant: Lilian Alcaraz et al. Attorney's Docket No.: 06275-518US1 / 101318-1P US

Serial No. : 10/587,633 Filed : July 28, 2006 Page : 4 of 8

26. (New) The compound of claim 23, wherein the acidic OH of R³ is a substituent or part of a substituent on a phenyl, naphthyl, furyl, thienyl, pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, pyridinyl or pyrimidinyl ring.

- 27. (New) The compound of claim 23, wherein the acidic OH of R³ is part of an acidic phenol, in a carboxylic acid or in a hydroxy aromatic heterocyclyl selected from the group consisting of a hydroxypyridine and a pyridone.
- 28. (New) The compound of claim 15, wherein R³ is 2-oxo-thiazol-5-yl having an electron withdrawing substituent in the 4-position selected from the group consisting of C₁₄ fluoroalkyl, aryl, heterocyclyl, and CH₂S(O)₂(C₁₄ alkyl).
- (New) The compound of claim 15, wherein R³ is 2-oxo-oxazol-5-yl having an
 electron withdrawing substituent in the 4-position selected from C₁₋₄ fluoroalkyl and
 CH₂S(O)₂(C₁₋₄ alkyl).
- 30. (New) The compound of claim 15, wherein R³ is 1H-1,2,3-triazol-4-yl having a substituent in the 5-position selected from the group consisting of C₁₋₄ alkyl; C₃₋₆ cycloalkyl; C₁₋₄ fluoroalkyl; S-R⁴ wherein R⁴ is C₁₋₄ alkyl, C₁₋₄ fluoroalkyl, or C₃₋₆ cycloalkyl; NHS(O)₂(C₁₋₄ alkyl); aryl; heterocyclyl; and CH₂S(O)₂(C₁₋₄ alkyl).
- 31. (New) The compound of claim 15, wherein \mathbb{R}^3 is 4-oxo-1H-1,4-dihydropyridin-3-yl having a $\mathbb{C}_{l\cdot 4}$ fluoroalkyl in the 2-position.
- 32. (New) The compound of claim 15, wherein R^3 is 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl having a substituent in the 3-position selected from the group consisting of $C_{1.4}$ alkyl, $C_{3.6}$ cycloalkyl, and $C_{1.4}$ fluoroalkyl.

Applicant: Lilian Alcaraz et al. Attorney's Docket No.: 06275-518US1 / 101318-1P US

Serial No. : 10/587,633 Filed : July 28, 2006

Page : 5 of 8

33. (New) The compound of claim 15, wherein R³ is 6-oxo-1H-1,6-dihydropyridin-3-yl having a electron withdrawing substituent the 2-position or the 5-position selected from the group consisting of C₁₋₄ fluoroalkyl and cyano, and wherein R³ is optionally substituted in other positions.

- (New) The compound of claim 15, wherein R³ is 2H-tetrazol-5-vl.
- (New) The compound of claim 15, wherein R³ is a CO₂H group on an optionally substituted phenyl or naphthyl ring.
- 36. (New) The compound of claim 15, wherein R^3 is an NHS(O)₂(C₁₋₄ alkyl) group on an optionally substituted aromatic heterocyclyl.
- 37. (New) The compound of claim 15, wherein R² is hydrogen or C₁-C₄ alkyl.
- (New) N-{(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-6oxo-2-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide.
- (New) N-{(2R)-3-[4-(2,4-Dichloro-3-methylphenoxy)piperidin-1-yl]-2hydroxypropyl}-6-oxo-2-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide.
- (New) 5-Bromo-N-{(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2hydroxypropyl}-6-oxo-2-(trifluoromethyl)-1.6-dihydropyridine-3-carboxamide.
- (New) N-{(2S)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-N-methyl-2-oxo-4-(trifluoromethyl)-2,3-dihydro-1,3-thiazole-5-carboxamide.
- 41. (New) N-{(2S)-3-[4-(2,4-Dichloro-3-methylphenoxy)piperidin-1-yl]-2-hydroxypropyl}-N-methyl-2-oxo-4-(trifluoromethyl)-2,3-dihydro-1,3-thiazole-5-carboxamide.

Attorney's Docket No.: 06275-518US1 / 101318-1P US

Applicant: Lilian Alcaraz et al. Serial No.: 10/587,633 Filed: July 28, 2006 Page: 6 of 8

42. (New) N-{(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-2-oxo-4-(pentafluoroethyl)-2.3-dihydro-1.3-thiazole-5-carboxamide.

- (New) N-{(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-5-methyl-1H-1.2.3-triazole-4-carboxamide.
- 44. (New) N-{(2R)-3-[4-(2,4-Dichloro-3-methylphenoxy)piperidin-1-yl]-2-hydroxypropyl}-5-methyl-1H-1,2,3-triazole-4-carboxamide.
- 45. (New) 5-Cyano-N-{(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-6-oxo-2-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide.
- $\label{eq:continuous} \begin{tabular}{ll} 46. & (New) 5-Cyano-N-{(2R)-3-[4-(2,4-dichloro-3-methyl)phenoxy)piperidin-1-yl]-2-hydroxypropyl}-6-oxo-2-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide. \end{tabular}$
- 47. (New) 5-Cyano-N-{(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-6-oxo-2-phenyl-1,6-dihydropyridine-3-carboxamide.
- 48. (New) 5-Cyano-N-{(2R)-3-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]-2-hydroxypropyl}-6-oxo-2-phenyl-1,6-dihydropyridine-3-carboxamide.
- (New) N-{(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-3-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamide.
- (New) N-{(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-2,6-dioxo-3-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyrimidine-4-carboxamide.
- (New) 5-Cyano-2-cyclopropyl-N-[(2R)-3-[4-(3,4-dichlorophenoxy)-1piperidinyl]-2-hydroxypropyl]-1,6-dihydro-6-oxo-3-pyridinecarboxamide.

Attorney's Docket No.: 06275-518US1 / 101318-1P US

Applicant: Lilian Alcaraz et al. Serial No.: 10/587,633 Filed: July 28, 2006

Page : 7 of 8

52. (New) 5-Cyano-2-cyclopropyl-N-[(2R)-3-[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]-2-hydroxypropyl]-1,6-dihydro-6-oxo-3-pyridinecarboxamide.

- 53. (New) N-{(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-6-[(methylsulfonyl)amino]-4-(trifluoromethyl)nicotinamide.
- 54. (New) N-{(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-5-[(2,2,2-trifluoroethyl)thio]-1H-1,2,3-triazole-4-carboxamide.
- $\label{eq:continuous} \begin{tabular}{ll} 55. & (New) $4-[(\{(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl\}amino)-carbonyl]-1-naphthoic acid. \end{tabular}$